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dorzolamide (P < 0.01). Seventy-ﬁve percent of the
patients had a treatment duration longer than 203 days
when treated with brinzolamide versus 140 days with
dorzolamide. The probability of a failure was 1.61 (P <
0.02) times higher with dorzolamide, after adjusting for
treatment line and the number of drugs prescribed. The
yearly glaucoma treatment cost for a patient with a treat-
ment failure was found to be higher (GBP 15.21) than for
patients who continued their treatment. CONCLUSION:
In comparison to dorzolamide, patients treated with brin-
zolamide experienced fewer treatment failures, leading to
cost savings.
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OBJECTIVES: The purpose of this study was to com-
pare the intraocular pressure (IOP)—lowering efﬁcacy
and cost-effectiveness of Lumigan (Bimatoprost) 
versus Xalatan (Latanoprost) in glaucoma patients.
METHODS: A Markov model was developed to compare
the cost-effectiveness of Lumigan initiated treatment with
Xalatan initiated treatment in the context of the French
Health care system. The model uses a timeframe of one
year and data from published randomised clinical trials,
which included a total of 249 patients. Patients were
allowed to switch medication up to a maximum of two
times if target IOP was not met or adverse events occurred
and each switch was associated with a physician visit
(cost: €23.00 each). Drug costs used were €20.10 for
Lumigan and €17.67 for Xalatan. A probabilistic analy-
sis was performed using 1000 Monte Carlo simulations.
The primary outcome measures were the number of
months patients spent at IOP < 17mmHg and the cost
per month at IOP < 17mmHg. Sensitivity analyses were
conducted varying the target IOPs. RESULTS: More
patient months at IOP < 17mmHg were achieved by
patients on Lumigan versus Xalatan initiated therapy (9.7
versus 9.3; P < 0.05). Lumigan initiated therapy was also
associated with fewer annual physician visits per patient
(5.14 compared to 5.48; P < 0.001). The cost per patient
per month at IOP < 17mmHg was €41.96 for patients on
Lumigan compared to €44.60 for those on a Xalatan ini-
tiated therapy. The results of the sensitivity analysis deter-
mined that at target IOPs of 14 to 17mmHg there was a
lower average annual treatment cost per patient for
Lumigan initiated patients. CONCLUSIONS: Lumigan
initiated treatment is more cost-effective than Xalatan ini-
tiated treatment at target IOPs between 14–17mmHg.
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OBJECTIVE: The aim of glaucoma treatment is to delay
progression of the disease to blindness, by lowering 
intra-ocular pressure (IOP). Clinical trials have shown
that latanoprost (Xalatan®, Pﬁzer) achieves better IOP
control than beta-blockers. We assessed the cost-
effectiveness of latanoprost as 1st-line therapy, compared
to beta-blockers, in Austria, Belgium, France, Germany,
Italy and the UK. METHODS: Clinical outcomes and
resource utilisation data were obtained from a retrospec-
tive chart review study of glaucoma patients initially
treated with latanoprost or beta-blocker in Germany,
Italy, Spain, and the UK. A Markov model was used to
calculate the number of months of IOP control and total
costs (including drugs, physician visits, diagnostic tests
and surgeries) per patient over 2 years from a third-party
payer perspective. The model was estimated by Monte
Carlo simulation. The incremental cost per IOP-
controlled month was reported for each country and 
variability around this ratio was examined. RESULTS:
Seventy-three percent of patients remained on treatment
with latanoprost, compared to 29% with beta-blocker,
over 2 years. The higher acquisition cost of latanoprost
was partly offset by lower surgery costs. The ICER ranged
from €24.94 (95% CI: 20.68–30.11) per IOP-controlled
month, for France, to €272.84 (251.24–297.17), for
Germany. Sensitivity analyses showed that survival on
therapy, the duration of medication bottles and parame-
ters related to surgery costs were the main drivers of 
cost-effectiveness. CONCLUSIONS: Differences between
countries were mainly attributable to variation in drug
and surgery unit costs. First-line treatment with
latanoprost is predicted to be cost-effective if decision-
makers value the control of IOP at a minimum of approx-
imately €25 per month in France, €45 per month in
Belgium, UK and €275 per month in Germany, under the
current system and costs of care. Relatively low unit costs
for surgery and the drug co-payment system contributed
to the higher ICER in Germany.
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OBJECTIVE: To quantify the effect of treatment dura-
tion on life-long societal net value of glaucoma treatment
according to its treatment line in three European coun-
tries. METHODS: A Markov model was used to repro-
duce the average discounted (5%) cost and outcome of
glaucoma treatment over 30 years. Clinical states were
ﬁrst to fourth line treatment, no treatment, laser, surgery,
blindness and death. All patients started ﬁrst line, went
successively to the next line after failure. After each
failure (and always after the fourth line) patients could
have either laser or surgery followed by no treatment, or
a new ﬁrst line treatment. Transition probabilities and
resource utilisation (RU) came from of a cross-sectional
study with 5 years retrospective data collection for 
the glaucoma treatment, and from national statistics in
France. Expert interviews were conducted in Germany
and the Netherlands to collect RU. In-patient and outpa-
tient direct medical costs and indirect costs were esti-
mated from a societal point of view. Sensitivity analyses
and second order Monte-Carlo simulation were per-
formed. RESULTS: Life expectancy of this cohort (57
years old on average, 52% females) was 23.2 years.
Patients spent 9.8 years in ﬁrst line, 4.2 in second, 3.0 in
third, 2.2 in fourth, 3.6 without treatment, had 0.35
lasers and 1.17 surgeries. These ﬁgures became, respec-
tively, 11.77, 3.36, 2.41, 1.86, 3.47, 0.36 and 1.054 if
ﬁrst line treatment duration increased by 30% and 9.35,
5.52, 2.55, 1.97, 3.46, 0.35, 1.079 for a 30% 2nd line
duration increased. In France, €430 and €108 were saved
for a 30% ﬁrst and second line increased, respectively.
These ﬁgures were €241 and €30 in Germany and €257
and €55 in the Netherlands. Patients spent less time in
long-term institution. CONCLUSION: Increasing ﬁrst
line or second line glaucoma treatment duration is a cost
saving approach over life of a patient according to our
model.
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OBJECTIVE: To compare model estimates of the cost-
effectiveness of latanoprost and travoprost versus timolol.
METHODS: The probability of developing a visual ﬁeld
defect (VFD) was estimated using data from a double-
masked double-dummy Phase III multi-centre clinical trial
comparing travoprost 0.004%od, latanoprost 0.005%
od and timolol 0.5%bid, and the 2 discriminant func-
tions published by Stewart (1993). A Markov model was
constructed to estimate the cost and effectiveness (time to
disease progression) of patients treated over ﬁve years for
two states: those who do and those who do not develop
a VFD. Resource utilisation was estimated from a 5-year
retrospective patient chart analysis in France, from the
UK General Practitioner Data Base in the UK, and from
expert interviews in Germany. Both costs and outcomes
were discounted at a 5% rate. The economic perspective
was that of the Heath Care Sick Fund. RESULTS: The
average time to disease progression was estimated to be
2.81 years with timolol, 3.28 with latanoprost and 3.42
with travoprost. In France, over 5 years, a latanoprost
treated-patient is predicted to cost 277.6 more than a
timolol-treated patient while the ﬁgure for a travoprost-
treated patient is EUR 403.7. In Germany, these ﬁgures
were €858.60 and €714.80, for latanoprost and travo-
prost respectively. The corresponding amounts in the UK
were €288.9 and €251.1. In the UK and in Germany,
travoprost was predicted to be more effective and less
costly than latanoprost. Comparing the prostaglandin
analogues in France, travoprost’s incremental additional
5 year cost is modelled to be €951.4 per additional disease
free year. CONCLUSION: According to our model,
travoprost is a cost-effective alternative to timolol and
latanoprost.
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OBJECTIVE: The aim of this study was to compare the
cost-effectiveness of intraocular lens material (PMMA,
silicone, acrylic hydrophilic, and hydrophobic) implanted
during cataract surgery with reference to Yag-laser cap-
sulotomy and Yag-laser complications in four European
countries (France, Italy, Germany and Spain). Setting: A
retrospective review of 1525 patients (eyes), aged 50 to
80 years, operated with phaco-emulsiﬁcation for cataract
in 1996 or 1997 in 16 surgical centres (4 per country).
METHODS: The study was conducted using a cost-
effectiveness approach. Medical charts were reviewed to
collect retrospective information during the 3-year period
following cataract surgery in order to identify patients
who underwent YAG laser capsulotomy post-operatively.
Clinical data were combined with unit costs assessed by
experts for Yag laser capsulotomy and Yag complications.
A cost-effectiveness ratio (cost per patient without Yag
laser capsultomy intervention) was estimated in relation
